{"id":"askb589","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, ASKB589 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"ASKB589 is a small molecule inhibitor of the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:13.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06206733","phase":"PHASE3","title":"ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2024-01-25","conditions":"Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma","enrollment":780},{"nctId":"NCT04632108","phase":"PHASE1, PHASE2","title":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","startDate":"2021-01-28","conditions":"Malignant Solid Tumor","enrollment":199},{"nctId":"NCT05632939","phase":"PHASE1, PHASE2","title":"ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2023-02-21","conditions":"Gastric Cancer, Gastroesophageal Cancer (GC)","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ASKB589","genericName":"ASKB589","companyName":"AskGene Pharma, Inc.","companyId":"askgene-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASKB589 is a small molecule inhibitor of the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}